Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pradefovir - Ligand Pharmaceuticals

Drug Profile

Pradefovir - Ligand Pharmaceuticals

Alternative Names: Hepavir B; ICN-2001-3; MB-06866; MB-6866; Pradefovir mesylate; Remofovir; Remofovir mesylate; UNII-GZE85Q9Q61

Latest Information Update: 30 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Chiva Pharmaceuticals; Ligand Pharmaceuticals; Valeant Pharmaceuticals International
  • Class Adenine nucleotides; Antivirals; Organophosphorus compounds; Purines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatitis B

Most Recent Events

  • 30 Jul 2019 Pradefovir is still in phase I development for Hepatitis B in China (Ligand Pharmaceuticals pipeline, July 2019)
  • 03 Feb 2016 Pradefovir is in development for Hepatitis B in China
  • 03 Feb 2016 Discontinued - Phase-II for Hepatitis B in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top